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Abstract
Aims: HMGB1 injection into the mouse heart, acutely after myocardial infarction (MI), improves left ventricular (LV) function
and prevents remodeling. Here, we examined the effect of HMGB1 in chronically failing hearts.
Methods and Results: Adult C57 BL16 female mice underwent coronary artery ligation; three weeks later 200 ng HMGB1 or
denatured HMGB1 (control) were injected in the peri-infarcted region of mouse failing hearts. Four weeks after treatment,
both echocardiography and hemodynamics demonstrated a significant improvement in LV function in HMGB1-treated
mice. Further, HMGB1-treated mice exhibited a ,23% reduction in LV volume, a ,48% increase in infarcted wall thickness
and a ,14% reduction in collagen deposition. HMGB1 induced cardiac regeneration and, within the infarcted region, it was
found a ,2-fold increase in c-kit
+ cell number, a ,13-fold increase in newly formed myocytes and a ,2-fold increase in
arteriole length density. HMGB1 also enhanced MMP2 and MMP9 activity and decreased TIMP-3 levels. Importantly, miR-206
expression 3 days after HMGB1 treatment was 4-5-fold higher than in control hearts and 20–25 fold higher that in sham
operated hearts. HMGB1 ability to increase miR-206 was confirmed in vitro, in cardiac fibroblasts. TIMP3 was identified as a
potential miR-206 target by TargetScan prediction analysis; further, in cultured cardiac fibroblasts, miR-206 gain- and loss-of-
function studies and luciferase reporter assays showed that TIMP3 is a direct target of miR-206.
Conclusions: HMGB1 injected into chronically failing hearts enhanced LV function and attenuated LV remodelling; these
effects were associated with cardiac regeneration, increased collagenolytic activity, miR-206 overexpression and miR-206 -
mediated inhibition of TIMP-3.
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Introduction
Although in recent years post-infarction survival rates have
improved, left ventricular failure due to loss of cardiomyocytes and
remodeling remains a major health problem; it has a poor prognosis
and represents the most frequent cause of hospitalization among
elderly adult patients. Current treatments that result in definite
clinical benefitsinhumansarerepresented byprompt reperfusion of
the ischemic myocardium and pharmacologic therapy mostly based
on the inhibition of the renin-angiotensin-aldosterone axis and the
sympathetic nervous system. It is noteworthy that these treatments
have no effect on contractile mass loss [1].
In the last years efforts have been performed to promote cardiac
tissue regeneration with bone marrow [2] and, recently, with
cardiac stem cell (CSC) transplantation [3]. Further, in animal
models, it has been shown that it is possible to promote resident
CSC proliferation and differentiation in vivo, by injecting cytokines
or growth factors directly into the heart either in the acute [4,5]
and chronic [6] phase following infarction.
High Mobility Group Box-1 protein (HMGB1) is a highly
conserved nuclear protein that acts as a chromatin-binding factor
capable of promoting access of transcriptional complexes to the
DNA. In addition to its nuclear role, HMGB1 functions as an
extracellular signalling molecule regulating both inflammation and
regenerating processes [7]. In presence of tissue damage, both
inflammatory and necrotic cells release HMGB1 and the
extracellular protein stimulates monocytes/macrophages and
neutrophils to secrete inflammatory cytokines amplifying the
inflammatory response. Further, in different in vivo models of
human diseases HMGB1 stimulates tissue repair [8]. Our
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e19845laboratory has shown that HMGB1 administration, acutely after
myocardial infarction, induces cardiac progenitor cell proliferation
and differentiation, myocardial regeneration and an improvement
in cardiac performance. This result is in agreement with other
studies which have examined HMGB1 ability to activate vessel
associated stem cells [9], endothelial progenitor cells (EPCs) [10]
and myogenic cells [11]. Taken together these results raise the
possibility that exogenous HMGB1 may be used to activate
resident stem cells and may have a therapeutic action that would
provide an alternative to cell transplantation. However, other
mechanisms which may account for HMGB1 therapeutic
potential in the context of ischemic cardiac damage are still
poorly characterized. In the present work we examined the effect
of exogenous HMGB1 in a murine model of heart failure and
found that HMGB1 intramyocardial injection improved left
ventricular (LV) function and remodelling; these effects were
associated with cardiac regeneration, increased collagenolytic
activity, miR-206 overexpression and miR-206 -mediated inhibi-
tion of tissue inhibitor of metalloproteinase 3 (TIMP-3).
Results
HMGB1 improves cardiac function, left ventricular
remodelling and mouse survival
We first examined whether HMGB1 injected into the LV wall
of failing hearts, three weeks after MI, had an effect on LV
function and remodelling, and on animal survival (Figure S1).
Echocardiographic studies were performed two weeks after MI,
i.e. one week prior to HMGB1 injection, and repeated 2 and 4
weeks following treatment. At the first time point, Ejection
Fraction (EF) was markedly lower (Figure 1A) and LV diameter in
diastole (LVDd) and in systole (LVDs) were higher (Figures 1B and
Figure 1. Echocardiography and hemodynamic studies after MI. Both echocardiographic and hemodynamic studies were performed to
evaluate LV function and size in infarcted mice (MI) treated with HMGB1 (HMGB1) or with denatured HMGB1 (control; C), and in sham operated
untreated mice (SO). (A–C) Echocardiography. LV ejection fraction (EF), LV diameter in diastole (LVDd) and LV diameter in systole (LVDs) were
measured 2 weeks after MI, before treatment, and again 5 and 7 weeks following MI, i.e. 2 and 4 weeks after HMGB1 or denatured HMGB1 injection
(SO, n=10; control, n=10; HMGB1, n=15). HMGB1 treatment improved EF and inhibited the progressive increase in LV dilation. (D,E) Hemodynamic
measurements were performed 7 weeks after MI, just before sacrifice. HMGB1 treatment ameliorated LV end-diastolic pressure (LVEDP) and LV
developed pressure (LVDP) (SO, n=10; control, n=14; HMGB1, n=19). Results are presented as mean6standard deviation.
doi:10.1371/journal.pone.0019845.g001
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importantly, infarcted mice, which were subsequently randomized
either to control or HMGB1 treatment, displayed similar
echocardiographic parameters.
HMGB1-injected animals exhibited a progressive increase in EF
whereas LV function of control mice progressively deteriorated
and, 4 weeks after treatment, the two groups were significantly
different (Figure 1A). Similarly, LVDd and LVDs progressively
increased in control whereas LV dilation was prevented in
HMGB1-treated animals (Figures 1B and C). It is noteworthy
that all echocardiographic measurements demonstrated an
improvement not only in HMGB1-treated mice compared to
untreated mice but also in HMGB1-treated animals, at the
different time points of the analysis (Figures 1A–C).
Hemodynamic measurements were performed 4 weeks after
treatment, prior to sacrifice, and, in agreement with the
echocardiograpic studies, confirmed the beneficial effect of
HMGB1 treatment. Specifically, HMGB1 attenuated the increase
in LV end-diastolic pressure (LVEDP; Figure 1D) and the
decrease in LV developed pressure (LVDP; Figure 1E); in
contrast, the effect on 6dP/dt was marginal and did not achieve
statistical significance (Figure S2). Further, the functional im-
provement in HMGB1-treated hearts was associated with a thicker
infarcted wall and reduced LV chamber dilation (Figures 2A and
2B). The attenuation in ventricular dilation together with the
hemodynamic parameters resulted in a reduction in diastolic free
wall and septal wall stress (Figures 2C and 2D).
Finally, the above functional and morphometric changes in
HMGB1-treated animals resulted in a significant increase in
survival during the 4 weeks following treatment (Figure 2E).
HMGB1 induces cardiac regeneration in failing hearts
We have previously shown that HMGB1 injected into the
mouse LV wall four hours after coronary artery ligation induces c-
kit
+ cell activation, myocardial regeneration and improvement in
cardiac function [5]. Here we examined whether HMGB1
induced myocardial regeneration also in the failing heart. In
agreement with our previous work we found that 3 days after
HMGB1 injection into the failing ventricle, the number of c-kit
+
cells in the infarcted area increased from 1.17 to 3.18 cells/mm
2
(p,0.05). Four weeks after treatment the infarcted region
exhibited a thicker wall (Figures 3A and B) with a mixture of
Figure 2. Cardiac anatomy, wall stress and animal survival after MI. Infarcted wall thickness was enhanced in HMGB1 vs control mice (A).
Further, HMGB1 attenuated the increase in LV volume (B), diastolic free wall stress (C) and diastolic septal wall stress (D) following MI. All measurements
were obtained 4 weeks after HMGB1 or control treatment (Results are presented as mean6standard deviation; SO, n=10; control, n=14; HMGB1,
n=18). (F) HMGB1 improved survival vs control during the 4 weeks following treatment (control, n=24; HMGB1, n=31; log-rank test, p,0.002).
doi:10.1371/journal.pone.0019845.g002
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of a thin band of small cells expressing the cardiac marker a-
sarcomeric actin, Ki67, a protein present in the nucleus of cycling
cells (Figure 3C) and BrdU incorporation (Figure 3D). Further,
these small cardiomyocytes expressed connexin 43, a protein
responsible for electrical coupling among myocytes. This protein
was present in the cytoplasm and at the surface of closely aligned
differentiating cells demonstrating that the new myocardial cells
were acquiring functional competence (Figure 3E). Treated hearts
generated an average 16.5 million new myocytes (Figure 4A) that
had volumes varying from 70 to 2000 mm
3 (Figure 4B) and were
localized within the infarcted area; altogether regeneration
accounted for 963.7 mm
3 of new myocardium (Figure 4C) and
resulted in 2465% recovery of scar tissue (Figure 4D). Since cell
survival is dependent upon blood flow, we also quantified
arterioles length density in the scar and in the non-infarcted left
ventricle. It has been previously demonstrated that HMGB1
induces angiogenesis, both in vitro and in vivo, in several animal
models of tissue damage [11,13,14]. In agreement with those
studies we found that, four weeks after HMGB1 administration,
the length density of arterioles 4 to 41 mm in diameter, detected by
anti-a-smooth muscle actin immunostaining, was significantly
enhanced in the scar region of the treated group compared to the
control group (Figure 4E); indeed, in the infarcted region there was
a significant decrease in arterioles and HMGB1 enhanced
arteriole length density to a level comparable to that in sham
operated mice. It is noteworthy that the increase in arteriole 4 to
21 mm in diameter accounted for this response and that the trend
increase in the length density of arterioles 21 to 41 mm in diameter
failed to achieve statistical significance (Figure S3).
HMGB1 reduces collagen deposition and enhances
collagenolytic activity in the infarcted region
In light of the effect of HMGB1 on LV volume and remodelling,
and of the significant recovery of scar tissue, we quantified
collagen deposition in the scar by Masson’s Trichrome staining
and quantitative digital image analysis. We found that, four weeks
after treatment, collagen density was 14% lower in HMGB1-
treated than in control hearts (Figure 5). In order to account for
this result it was evaluated whether HMGB1 had an effect on the
expression of matrix metalloproteinases (MMPs) and their
inhibitors (TIMPs), and whether collagenolytic activity was
modulated. Failing hearts expressed MMP-2 and MMP-9
(Figures 6A and 6B); HMGB1 administration had no significant
effect on MMP-2 mRNA and protein levels (Figures 6A and 6C)
whereas it markedly enhanced MMP-9 mRNA and protein
(Figures 6B and 6C). Further, both MMP-2 and MMP-9
collagenolytic activity increased in the infarcted area of HMGB-
1 treated hearts (Figure 6D). Since among the four known TIMPs
only TIMP-3 inhibits both MMP-2 and MMP-9 activity [15], we
examined the protein level of this inhibitor; we found that TIMP-3
in the border zone and in the infarcted area was lower than in the
left ventricle of sham operated hearts and that HMGB1 caused a
further decrease in TIMP-3 protein (Figure 6E). In contrast, there
was no effect of HMGB1 on TIMP-4 expression (Figure S4).
HMGB1 induces miR-206 expression in vivo and in vitro
Several miRNA have been involved in the regulation of
myocardial cell proliferation and differentiation, cytoskeletal
organization, cardiac hypertrophy and fibrosis [16,17]. Therefore,
Figure 3. Newly formed cardiomyocytes in the failing heart. (A,B) Representative H&E stained myocardial sections of the infarcted region
from control (A) and HMGB1-treated mice (B). (C–E) Regenerated myocytes in the infarcted region of HMGB1-treated hearts expressed a-sarcomeric
actin (red fluorescence) in the cytoplasm, the nuclear protein Ki-67 (C) and evidence of BrdU incorporation (arrows) in the nucleus (D). Newly formed
myocytes in the infarcted area were positive for connexin 43 (E; green fluorescence). Representative cells are shown at higher magnification in the
inset. Nuclei are stained with DAPI.
doi:10.1371/journal.pone.0019845.g003
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HMGB1 had an effect on miRNAs known to play an important
role in modulating cardiac structure and function. In agreement
with prior studies in animal models of heart failure it was found
that miR-21 and miR-208b increased both in the infarct area and
in the border zone, miR-1 and miR-208a decreased in the infarct
area, miR-133a decreased in the border zone whereas the trend
decrease in the infarct area did not achieve statistical significance,
Figure 4. Cardiac regeneration in failing hearts. (A) Average number and (B) volume distribution of regenerated myocytes (control, n=11;
HMGB1, n=13). (C) Average new myocardium volume in HMGB1-treated and control hearts (n=13). (D) Reduction of infarct size by tissue
regeneration: myocardium volume of the left ventricle in SO mice (n=10) and volume of remaining (Re), lost (Lo) and regenerated (New) myocardium
in HMGB1-treated (n=13) and control (n=11) animals. (E) Average arteriole length density (diameter 4–41 mm) in the scar tissue and in the remaining
(Re) myocardium of control (C; n=10) and HMGB1-treated (HMGB1; n=10) hearts. Arteriole length density was also evaluated in the LV of SO mice.
(n=10). All measurements were performed 4 weeks after HMGB1 or control treatment.
doi:10.1371/journal.pone.0019845.g004
Figure 5. Collagen in the failing heart. (A) Representative Masson’s Trichrome staining photomicrographs of control (C) and HMGB1-treated
(HMGB1) hearts, 4 weeks after treatment. (B) Average results show a lower collagen content in HMGB1-treated (HMGB1; n=14) than in control (C;
n=10) hearts.
doi:10.1371/journal.pone.0019845.g005
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e19845Figure 6. MMP-2, MMP-9, TIMP-3 expression and collagenolytic activity in the failing heart. All experiments depicted in this figure were
performed three days after HMGB1 or control treatment. Both MMP-2 (A) and MMP-9 (B) mRNAs increased in the infarcted heart; HMGB1 had no effect
on MMP-2 expression (n=5) whereas it enhanced MMP-9 expression (n=5), both in the border zone and in the infarcted area. (C) HMGB1 increased
MMP-9protein in theinfarcted area whereas ithadnosignificanteffect onMMP-2protein.(D) HMGB1markedlyincreasedMMP-2andMMP-9 gelatinase
activity in the infarcted area vs control hearts. This experiment was repeated 3 times with similar results. (E) TIMP-3 protein levels were lower in failing
hearts, both in the border zone and in the infarcted area, than in SO hearts. HMGB1 caused a further decrease in TIMP-3 protein. Both for MMPs (C) and
TIMP-3, the same filter was probed with a-tubulin to normalize protein loading (n=5 for the average results of densitometric analyses of western blots).
doi:10.1371/journal.pone.0019845.g006
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the infarct and in the border zone [18–22] (Figure S5). Further,
although miR-29 family has been involved in post-MI fibrosis
through the regulation of collagen [23], no significant expression
changes were observed in our experimental model between healthy
and failing hearts (Figure S5). None of these miRNAs was
significantly modulated by HMGB1 except for miR-133b further
diminutioninthe infarctarea ofHMGB1-treatedhearts(FigureS5).
In contrast, muscle specific miR-206, which has been previously
shown to increase acutely after MI [24], was markedly up-regulated
in failing hearts (Figure 7A) and, following treatment with HMGB1,
itexhibiteda ,4–5-foldadditionalincrease,bothintheborderzone
and in the infarct area (Figure 7A), which represented a ,20–25
fold increase vs the LV expression level in sham operated mice
Additional experiments were performed in vitro to confirm HMGB1
effect on miR-206 expression. Cardiac fibroblasts (CFs) were
isolated from adult mouse hearts and cultured for 24 hr under
normoxicorhypoxicconditions,eitherinthepresence orabsenceof
HMGB1. Both in normoxia and hypoxia, HMGB1 enhanced miR-
206 expression and this response was more pronounced at low
oxygen concentration (Figure 7B).
miR-206 down-modulates TIMP-3 expression
Since HMGB1 up-regulates miR206 expression, we sought to
clarify the possible functions of this miRNA in HMGB1-mediated
effects in failing hearts. A bioinformatics-based approach was
employed to predict the putative mRNA targets containing
evolutionarily conserved miR-206 seed match sequences in their
39UTRs [25–27]. Notably, among potential candidates we
identified TIMP-3 which we had found down-modulated in failing
hearts following HMGB1 administration (Figure 6E). The in vitro
experiments were performed in CFs isolated from mouse hearts and
cultured either in normoxic or in hypoxic conditions. CFs expressed
MMP-2 and MMP-9 and HMGB1 administration to the culture
medium enhanced both MMPs expression in hypoxic cells (Figure
S6). This effect was paralleled by a significant decrease of TIMP-3
mRNA and protein levels under hypoxia (Figures 8A and 8B).
To corroborate these results, we performed miR-206 gain-
and loss-of-function experiments and measured TIMP-3. Over-
expression of miR-206 in normoxic conditions significantly
reduced TIMP-3 mRNA (Figure 9A) and protein levels
(Figure 9B). Further, knockdown of endogenous miR-206 by
anti-miR-206 counteracted HMGB1-mediated down-regulation
of TIMP-3 protein levels (Figure 9C). In order to establish
whether miR-206 targets TIMP-3 mRNA directly, a luciferase
reporter assay was performed. Two complementary base pair
matching sequences for miR-206 were located at 1090–1097 and
at 1683–1689 of the TIMP-3-39UTR. Interestingly, both seed
sequences of TIMP-3-39UTR to miR-206 are highly conserved
among species and are identical in mouse, rat, dog, cow and
human (Figure 9D). To validate whether miR-206 recognizes the
39UTR of TIMP-3, two constructs containing each miR-206
seed sequence and the immediately surrounding sequences in
TIMP-3 were cloned downstream of the luciferase open reading
frame; pLUC-1090/97 and pLUC-1683/89 (Figure 9E and data
not shown). The luciferase activity of each construct was
evaluated following their cotransfection in HEK-293 cells either
with miR-206 or a negative control miRNA. Luciferase activity
from pLUC-1683/89 was markedly inhibited by miR-206
overexpression whereas this effect was prevented by the deletion
of the seed complementary nucleotides in pLUC-M (Figure 9E);
in contrast, miR-206 seed-pairing site at position 1090/97 was
not functional in the assayed conditions (data not shown). Thus,
the seed sequence 1683/89 represents the specific target of
miR-206 and is responsible for miR-206-mediated TIMP-3
down-regulation.
Discussion
In the present study we demonstrated that HMGB1 injected
into murine chronically failing hearts enhanced LV function and
attenuated LV remodelling; these effects were associated with
myocardial and vascular regeneration, increased MMP-2 and
MMP-9 activity, miR-206 overexpression and miR-206 -mediated
inhibition of TIMP-3.
Figure 7. HMGB1 enhances miR-206 expression in failing hearts and in cardiac fibroblasts. (A) qRT-PCR analysis of miR-206 expression in
the border zone and in the infarcted area of HMGB1-treated and control hearts 3 days after treatment, as well as in the left ventricle of SO mice (n=5/
group). In failing hearts, three weeks after MI, there was a significant increase in miR-206 expression, both in the border zone and in the infarcted
area; HMGB1 had an additional effect to markedly enhance miR-206 expression. (B) qRT-PCR analysis of miR-206 expression in 24 hr normoxic and
hypoxic cultured CFs. HMGB1 (100 ng/ml) enhanced miR-206 expression both in normoxia and hypoxia (n=3/group).
doi:10.1371/journal.pone.0019845.g007
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been previously examined in acute MI, ischemia/reperfusion
injury and post-MI heart failure. Our laboratory has shown that
HMGB1 administration, acutely after MI, induces cardiac
progenitor cell activation, myocardial regeneration and an
improvement in cardiac performance [5]. Further, it has been
shown that coronary artery ligation in transgenic mice with
cardiac-specific overexpression of HMGB1 resulted, four weeks
after MI, in enhanced angiogenesis, improved survival and
restored cardiac function [28]. In agreement with those results,
HMGB1 blockade by administration of neutralizing anti-HMGB1
antibody in a rat model of MI worsened cardiac remodelling [29].
The effect of HMGB1 in ischemia/reperfusion injury has been
addressed in three separate studies and the results have been
controversial. The systemic administration of an anti-HMGB1
antibody to block endogenous HMGB1 worsened cardiac damage
[30] and exogenous HMGB1 administered via the perfusate to the
whole heart in a Langendorff preparation had a beneficial effect
[31]. In contrast, another study reported that exogenous HMGB1
administered intraperitoneally worsened cardiac damage whereas
the opposite result was achieved by endogenous HMGB1
inhibition with the intraperitoneal injection of HMGB1 boxA
[32]. Finally, two prior studies have examined the effects of
HMGB1 in failing hearts [33,34]. Volz et al. showed that
HMGB1-specific blockage significantly reduced post-myocardial
infarction remodeling. Notably, this effect was not detected in
mice lacking the HMGB1 receptor RAGE. Takahashi et al.
utilized a rat model of post-MI heart failure and an experimental
protocol similar to the one adopted in the present work, i.e. three
weeks after coronary ligation HMGB1 was injected intramyocar-
dially at a dose that, adjusted by weight, was similar to the dose
injected in our protocol; thereafter mice were followed for four
additional weeks. Interestingly, it was found an improvement in
ejection fraction and a decrease in extracellular collagen
deposition; those results were confirmed in the present study.
However, differently from Takahashi et al, in our work we also
demonstrated an increase in newly formed myocardial cells and an
increase in arteriole length density in the infarcted area. Further,
we found a marked increase in MMP-2 and MMP-9 activity and a
decrease in TIMP-3 expression. No prior study has shown an
effect of HMGB1 on MMP-2 and TIMP-3 whereas it has been
recently reported that HMGB1 enhances MMP-9 expression in
neurons, via Toll-Like Receptor 4 signaling [35], and in cancer
cells via NF-kB signalling [36]. Indeed, NF-kB is the intracellular
target of HMGB1 and its activation results in cell migration [37]
and in the modulation of the inflammatory response [38]. It is
noteworthy that enhanced MMPs activity may favour the
migration of activated resident progenitor cells into the scar and
cardiac regeneration as it has been shown to occur in response to
the intramyocardial injection of hepatocyte growth factor (HGF)
and insulin-like growth factor-1 (IGF-1)[6]. Activated MMPs can
be directly inhibited by interaction with TIMPs resulting in the
prevention of matrix degradation [39]. TIMP-3 is highly expressed
in the heart and inhibits different MMPs including MMP-2 and
MMP-9; further, it differs from other TIMPs because it binds
ECM which may lead to prolonged bioavailability, localized
action and a major effect on LV remodelling and fibrosis. Indeed,
TIMP-3 levels are significantly reduced in patients with dilated
cardiomyopathy and heart failure [40]. The present work confirms
that in the failing heart TIMP-3 expression is lower than in control
and also shows that HMGB1 consistently causes a further decrease
in TIMP-3 expression, both in vivo, in the infarcted area, and in
vitro, in hypoxic CFs. Inhibition of TIMP-3 expression is expected
to contribute to the increase in MMP-2 and MMP-9 activities and
the decrease in collagen content in HMGB1-treated failing hearts.
However, there are also important MMPs-independent effects of
TIMP-3 that should be considered. TIMP-3 inhibits neonatal
cardiomyocyte proliferation [15] and myogenic differentiation of
muscle stem cells [41], enhances CFs activation, phenotypic
differentiation toward myofibroblasts and BrDU incorporation
[42], promotes smooth muscle cell apoptosis [15] and inhibits
VEGF-induced angiogenesis in vitro and in vivo [43]. Further, the
hearts of TIMP-3-deficient mice after MI [44,45] exhibit
decreased collagen content and increased blood vessel density.
Notably, HMGB1 also enhances VEGF release from CFs [46],
suggesting that multiple mechanisms may be involved in the
Figure 8. HMGB1 reduces TIMP3 in cardiac fibroblasts. CFs were cultured under normoxic or hypoxic conditions for 24 hrs, either in the
presence or absence of 100 ng/ml HMGB1. Under hypoxic conditions both TIMP-3 mRNA (A) and protein (B) diminished upon exposure to HMGB1
(n=3/group).
doi:10.1371/journal.pone.0019845.g008
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studies[10,13,47,11]. Thus, TIMP-3 inhibition may account for
different HMGB1 effects in the failing heart; enhanced MMP-2
and MMP-9 activity that leads to a decrease in collagen in the
failing left ventricle, enhanced angiogenesis and increased cardiac
stem cell proliferation and differentiation that ultimately leads to
myocardial regeneration.
Recent reports have shown the involvement of a variety of
miRNAs in cardiac disease and, specifically, in cardiac remodel-
ling and fibrosis [17], however, under our experimental conditions
HMGB1 did not modulate these miRNA. In contrast, miR-206
increased in the failing LV and HMGB1 had a marked effect to
further increase miR-206 expression, both in the border zone and
in the infarcted area. In agreement with this result, HMGB1
Figure 9. miR-206 targets TIMP-3. Lentivirus-mediated miR-206 overexpression in hypoxic CFs inhibited TIMP-3 mRNA (A) and protein (B) levels.
TIMP-3 mRNA and protein were analyzed 3 and 24 hr after infection, respectively. Average results of densitometric analyses of western blot are also
shown. (C) Representative western blot shows that the effect of HMGB1 to decrease TIMP-3 protein in hypoxic CFs was rescued by anti-miR-206. Cells
were transfected with anti-miR206 and exposed to hypoxia for 24 hr either in the presence or in the absence of 100 ng/ml HMGB1. For western blot
analysis (B,C), the same filter was probed with a-tubulin to normalize protein loading. (D) Upper panel: Conservation of miR-206 seed match
sequences (in red and blue) in mammalian TIMP-3. Lower panel: Diagram of plasmid construction; the TIMP-3-39UTR containing the 1683-1689 seed
sequence (1651–1707) or the respective mutated segment were cloned downstream of the luciferase encoding sequence. (E) HEK293 cells were
transfected with vector alone (pLUC) or firefly luciferase constructs that contain either the intact (pLUC-1683–1689) or the mutated (pLUC-M) miR-206
binging site. Each plasmid was cotransfected with a plasmid encoding Renilla luciferase along with miR-206 or scramble sequence. Firefly luciferase
values were normalized to Renilla luciferase activity and the ratio of luciferase activity of each construct in the presence and in the absence of miR206
was calculated. Luciferase activity decreased upon pLUC-1683–1689 and miR-206 transfection whereas it was not modulated by cotransfection of
pLUC-M and miR-206 (n=6/group). These results indicate that miR-206 binds the 1683–1689 seed sequence in TIMP-3-39UTR.
doi:10.1371/journal.pone.0019845.g009
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Interestingly miR-206 has been extensively characterized in
skeletal muscle development; it plays a major role in muscle
differentiation [48] and is highly expressed in regenerating muscle
fibers, both in Duchenne Muscle Dystrophy and several days after
acute hindlimb ischemia [49]. Further, miR-206 overexpression in
C2C12 myoblasts has been recently shown to downregulate
TIMP-3 mRNA [41]. Regarding the heart, it has been shown only
that miR-206 increases after MI [24] but its functional role is
unexplored. In light of the major effect of HMGB1 on miR-206
we performed gain- and loss-of-function studies, established that
miR-206 modulates TIMP-3 mRNA and protein and, in a
luciferase reporter assay, we identified the seed sequence 1683/89
as the specific target of miR-206 responsible for TIMP-3 down-
regulation.
In conclusion, here we provide new insights into the
mechanisms by which HMGB1 induces myocardial regeneration,
new blood vessel development, prevents remodelling and improves
function in the failing heart. Importantly, miR-206-mediated
down-regulation of TIMP-3 may underlie some of the cardiac
effects of exogenous HMGB1 described in prior studies and in the
present work.
Materials and Methods
All experimental procedures in mice complied with the
Guidelines of the Italian National Institutes of Health, with the
Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Academy of Sciences,
Bethesda, MD, USA) and were approved by the Institutional
Animal Care and Use Committee. The approval number is
MM39.
An expanded Materials and Methods section containing details
for in vivo studies, cell isolation and culture, immunohistochem-
istry, western blot, gel zymography, mRNA and miRNA isolation
and amplification can be found in Materials and Methods S1.
miR-206 Overexpression and Down-modulation
To overexpress miR-206, miR-206 mimic or a control scramble
sequence (Table S1, Applied Biosystems) were transfected by small
interfering RNA transfection reagent (Santa Cruz Biotechnology)
in 70% confluent cardiac fibroblasts at the final concentration of
40 and 240 nM for mir-206 overexpression and inhibition,
respectively. To block endogenous miR-206, locked Nucleic Acid
oligonucleotides against miR-206 or a control scramble sequence
were transfected using the same protocol. After 16 h, cells were re-
fed with fresh medium, maintained either in normoxia or exposed
to hypoxia and experiments were performed up to 24 h later.
Reporter plasmid generation, expression and luciferase
assay
A luciferase reporter vector (pMir-Report; Ambion, Inc, Austin,
Tex. USA) was used to generate the luciferase constructs.
Oligonucleotides bearing wt or deleted miR-206-seed pairing sites
of TIMP-3 gene downstream of the stop codon (Table S1) were
cloned in pMIR-REPORT-Luciferase (pLUC, Ambion Inc.),
between SpeI and Hind III restriction sites. The oligonucleotides
used are listed in Table S1. The PCR products were then digested
with HindIII and SPEI, and the fragment was inserted into a
HindIII and SPEI -digested pMir-Report luciferase plasmid, to
obtain a luciferase construct pLuc1683/89 and pLuc 1090/97.
Mutant construct were generated using similar approach.
HEK-293 cells, plated in 24 well-plate, were transfected with
100 ng of pLUC, pLuc1683/89, pLuc 1090/97 pLuc1683/89M
and pLuc 1090/97M, 10 pmol of miR-206 scramble, and 2.5 ng
of pRL-null renilla luciferase. Cellular extracts were tested with
Dual Luciferase Assay (Promega, Milan, IT), according to the
manufacturer instructions, 48 hrs after transfection, using a
Synergy HT luminometer (BioTek Instruments, Winooski, VT
USA). Values were normalized according to renilla luciferase and
the ratio of firefly luciferase of each construct was calculated either
in the presence or in the absence of exogenous miR-206.
Data collections and Statistics
Results are presented as mean6standard error unless otherwise
indicated. Statistical significance between two measurements was
evaluated by unpaired Student’s t test and multiple comparisons
was performed by Bonferroni method [12]. A probability value of
p,0.05 was considered significant.
Supporting Information
Figure S1 Experimental protocol. Myocardial infarction
(MI) was induced in mice by coronary artery ligation. After 2
weeks, echocardiographic measurements were performed to
evaluate LV function and size. One week later, HMGB1 or
denatured HMGB1 (control; C) was injected in the peri-infarct
area. Echocardiography was repeated 2 weeks after injection (5
weeks after MI) and, again 4 weeks after injection (7 weeks after
MI); the last echocardiogram was followed by hemodynamic
evaluation, thereafter mice were sacrificed.
(TIF)
Figure S2 Hemodynamic assessment of cardiac func-
tion. (A) LV+dP/dt (rate of pressure rise) and (B) LV -dP/dt (rate
of pressure decay) in sham operated (SO), control (C) and
HMGB1-treated infarcted mice (MI). Measurements were ob-
tained 4 weeks after HMGB1 treatment (7 weeks after MI) (Results
are presented as mean6standard deviation; SO, n=10; control,
n=14; HMGB1, n=19).
(TIF)
Figure S3 HMGB1 enhances arteriole density in failing
hearts. (A) Representative photomicrograph of an arteriole in the
infarcted region of a HMGB1-treated heart, 4 weeks after
treatment; the arteriole is stained with a a-smooth muscle actin
antibody. (B–D) Bar graph showing arteriole length density.
Arterioles were grouped according to their diameter (4–10.99 mm;
11–20.99 mm; 21–40.99 mm) and were quantified in the scar tissue
and in the remaining myocardium (Re) of control (C; n=10) and
HMGB1-treated (HMGB1; n=10) hearts as well as in the LV of
SO mice (n=10).
(TIF)
Figure S4 HMGB1 does not modulate TIMP-4 expres-
sion. HMGB1 was injected into the LV three weeks after MI;
three days after HMGB1 injection it was found no modulation of
TIMP-4 mRNA expression vs control. Values in bar graphs are
reported as fold change vs control (n=3/group).
(TIF)
Figure S5 Effect of HMGB1 on cardiac miRNAs expres-
sion. HMGB1 was injected into the LV three weeks after MI;
three days after HMGB1 injection the expression of the indicated
miRNAs was evaluated by qRT-PCR both in the border zone and
in the infarcted area. Values are reported as fold change vs SO
hearts (n=5/group).
(TIF)
Figure S6 Effect of HMGB1 on MMP-2 and MMP-9
expression in cultured cardiac fibroblasts. MMP2 (A) and
HMGB1, miR-206 and Heart Failure
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e19845MMP9 (B) mRNA levels were determined in CFs cultured in
normoxia or hypoxia and treated with HMGB1 (100 ng/ml) for
6 hr (n=3/group).All values arereported as fold change vs control.
(TIF)
Table S1 miRNA and mRNA.
(PPT)
Materials and Methods S1 Details of in vivo studies including
the heart failure animal model as well as the functional and
histological evaluation of failing hearts, cell isolation and culture,
gel zymography western blot and miRNA studies, were described
in Materials and Methods S1.
(DOC)
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